Pfizer and BioNTech may have a strong pedigree in the mRNA vaccine game, but, when it comes to flu, they’ve run up against the same problem as their peers—neutralizing influenza strain B. The two ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...

Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...

It seeks an overnight block trade of about 4.55 million American depositary receipts, priced between $108 and $111.70 apiece, according to a Bloomberg report. The sale could fetch roughly $508 million ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...

Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve ...

Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK. GSK on ...

A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...